A panel of experts assembled by HOYA Vision Care have shared their consensus on the effectiveness of combining spectacle lenses and atropine drops for myopia management in children.
HOYA Vision Care hosted a virtual advisory meeting where five well-known experts in paediatric myopia discussed their opinions on combination treatment with atropine and optical inventions for myopia management.
The advisory group, comprising key experts from Europe and Asia, including Professor Hakan Kaymak from Internationale Innovative Ophthalmochirurgie in, Duesseldorf, Germany, shared insights based on their clinical experience and research.
Mr Pascal Blaser, global medical affairs manager myopia at HOYA Vision Care, said the company was pleased to be able to bring together the group of experts “to facilitate discussions on the latest treatment options including the combination of optical and pharmaceutical treatments”.
“The experts in the advisory meeting agreed that in order to prevent vision complications later in life, early detection, proper diagnostic measurement and treatment of myopia in children is critical,” he said.
The experts shared and discussed their experience with the MiYOSMART spectacle lens, including the results of a clinical application of the MiYOSMART spectacle lens in combination with 0.01% atropine drops in European myopic children and adolescents when the expected goal using the spectacle lens was not achieved.
They noted a better control effect with the combination treatment. They reported no significant changes in visual acuity or binocular vision between the use of MiYOSMART spectacle lenses alone or in combination with low dosage atropine.
These data shared by the experts, were recently presented at the International Myopia Conference held in Rotterdam, The Netherlands, along with research presented by Professor Kaymak on his study of axial length growth under treatment with MiYOSMART spectacle lenses and atropine.
A key outcome of the advisory meeting was the group reaching consensus on the use of the combination treatment combining HOYA’s MiYOSMART spectacle lenses and atropine drops for myopia management in children.
“The promising early treatment intervention I have seen in my work combining the MiYOSMART spectacle lens and atropine drops is a very exciting development as we continue to seek an evidence-based approach to myopia management in children,” Kaymak said.
“The consensus reached at HOYA’s advisory meeting on the combination treatment protocol helps eyecare professionals make informed decisions in addressing the growing global challenge of myopia.”
Since its launch in 2018, MiYOSMART is available in more than 28 markets with over two million spectacle lenses purchased by parents around the world.
MiYOSMART has not been approved for myopia management in all countries, including the US, but is available in Australia.
More reading
HOYA campaign driving consumers into MiYOSMART accredited practices
A myopia first: Hoya lens shows long-term efficacy
Hoya launches Oliver Wolfe Junior frames
